Глобальный рынок атеросклероза – тенденции отрасли и прогноз до 2029 года

Анализ и размер рынка

Сужение вены в результате образования бляшек известно как атеросклероз. Атеросклероз — это тип артериосклероза, который поражает артерии. Это состояние нарушает ток крови по всему телу, создавая серьезные сердечно-сосудистые риски. Когда эндотелий поврежден, холестерин ЛПНП накапливается в стенке артерии, вызывая атеросклероз. Чтобы очистить холестерин, организм посылает макрофагальные белые тромбоциты. Однако иногда клетки могут застревать в пораженном месте. Через некоторое время образуется бляшка, которая состоит из плохого холестерина (холестерина ЛПНП) и макрофагальных белых тромбоцитов. Бляшка перекрывает коридор, в результате чего нарушается кровоток по всему телу.

По данным Data Bridge Market Research, рынок атеросклероза в 2021 году оценивался в 2,55 млрд долларов США, а к 2029 году, как ожидается, достигнет 4,11 млрд долларов США, что соответствует среднегодовому темпу роста (CAGR) в 6,16% в прогнозируемый период с 2022 по 2029 год. Помимо таких данных о рынке, как рыночная стоимость, темпы роста, сегменты рынка, географический охват, участники рынка и рыночный сценарий, отчет о рынке, подготовленный командой Data Bridge Market Research, также включает в себя углубленный экспертный анализ, эпидемиологию пациентов, анализ перспективных направлений, анализ ценообразования и нормативно-правовую базу.

Область отчета и сегментация рынка

Определение рынка

Затвердение и сужение артерий, вызванное холестериновыми бляшками, выстилающими артерии с течением времени, известно как атеросклероз. Атеросклероз можно замедлить, если не остановить, с помощью лекарств от высокого уровня холестерина и высокого кровяного давления. Они снижают вероятность сердечного приступа или инсульта. Врач может использовать более инвазивные процедуры для разблокировки атеросклеротических закупорок. Шунтирование заключается в отведении крови вокруг заблокированной или суженной артерии с помощью сосуда из другой части тела или синтетической трубки. Тромболитическая терапия подразумевает инъекцию лекарства в пораженную артерию для растворения тромба. Бляшка удаляется из артерий с помощью катетера с острым лезвием на одном конце, что называется атерэктомией .

Динамика рынка атеросклероза

Драйверы

• Рост распространенности сердечно-сосудистых заболеваний

Рост распространенности сердечно-сосудистых заболеваний во всем мире, как ожидается, усилит рост рынка. По данным Европейской кардиологической сети, сердечно-сосудистые заболевания ежегодно поражают 3,9 миллиона человек в Европе, а в Европейском союзе от них умирают более 1,8 миллиона человек. В богатых странах малоподвижный образ жизни является причиной самых высоких показателей сердечно-сосудистых заболеваний. Кроме того, ожидается, что исследуемый рынок будет обусловлен малоподвижным образом жизни, что приведет к высокой распространенности сердечно-сосудистых заболеваний и повышению осведомленности о вариантах лечения.

• Увеличение инвестиций в инфраструктуру здравоохранения

Another significant factor influencing the growth rate of atherosclerosis market is the rising healthcare expenditure which helps in improving its infrastructure. Also, various government organizations aims to improve the healthcare infrastructure by increasing funding and this will further influence the market dynamics.

• Growing number of geriatric population

The surging geriatric population is estimated to enhance the market's expansion during the forecast period of 2022-2029. According to the World Health Organization (WHO), the worldwide geriatric population, which was estimated to be over 524 million in 2010, is expected to increase to nearly 2 billion by 2050. Due to their compromised immune systems, geriatrics are more susceptible to cardiovascular diseases, further estimated to enhance the risk of atherosclerosis in this age group.

• Rising incidences of high cholesterol and obesity

The rising incidences of obesity and high cholesterol is expected to flourish the market's growth rate by increasing the risk of atherosclerosis. In 2018, the World Health Organization estimates that 40 million children under the age of five were overweight or obese, according to the world health organization (WHO). Increased consumption of high-fat, high-sugar foods and rise in physical immobility due to the increasingly inactive nature of many types of work, changing modes of transportation, and increasing urbanization are all contributing to high cholesterol rates, resulting in high growth of market.

Furthermore, rising initiatives by public and private organizations to spread awareness will expand the atherosclerosis market. Additionally, the sedentary lifestyle of people such as high alcohol consumption and addiction of smoking will result in the expansion of atherosclerosis market. Rising level of disposable income and high prevalence of high blood pressure are the major factors anticipated to flourish the market's growth rate during the forecast period of 2022-2029.

Opportunities

• Increase in the number of research and development activities       

Moreover, the market's growth is fueled by an increase in the number of research and development activities. This will provide beneficial opportunities for the atherosclerosis market growth. Along with this, rising drug approvals and launches will further propel the market's growth rate. 

• Popularity of Generic Drugs

Due to several recalls of valsartan products manufactured by several brands, the US Food and Medication Administration approved a novel generic drug of Diovan in March 2019 to bridge the high demand and poor supply gap of this vital drug. After two months, Zydus Cadila reported that Chlorthalidone, a generic counterpart of Thalitone made by Pfizer, had been approved. This will create new market opportunities in coming years.

Moreover, rising investment for the development of advanced technologies and an increase in the number of emerging markets will provide beneficial opportunities for atherosclerosis market growth during the forecast period.

Restraints/Challenges

On the other hand, the high cost associated with the treatment will obstruct the market's growth rate. The dearth of skilled professionals and lack of healthcare infrastructure in developing economies will challenge the atherosclerosis market. Additionally, strict regulatory policies and lack of awareness among people will restrain and further impede the growth rate of the market during the forecast period of 2022-2029.

This atherosclerosis market report provides details of new recent developments, trade regulations, import-export analysis, production analysis, value chain optimization, market share, impact of domestic and localized market players, analyses opportunities in terms of emerging revenue pockets, changes in market regulations, strategic market growth analysis, market size, category market growths, application niches and dominance, product approvals, product launches, geographic expansions, technological innovations in the market. To gain more info on the atherosclerosis market contact Data Bridge Market Research for an Analyst Brief, our team will help you take an informed market decision to achieve market growth.

Patient Epidemiology Analysis

Atherosclerosis market also provides you with detailed market analysis for patient analysis, prognosis and cures. Prevalence, incidence, mortality, adherence rates are some of the data variables that are available in the report. Direct or indirect impact analyses of epidemiology to market growth are analysed to create a more robust and cohort multivariate statistical model for forecasting the market in the growth period.

Global Atherosclerosis Market Scope

The atherosclerosis market is segmented on the basis of stages, diagnosis, treatment, route of administration, end-users and distribution channel. The growth amongst these segments will help you analyze meagre growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Stages

• Endothelial Damage and Immune Response
• Fatty Streak
• Plaque Growth
• Plaque Rupture

Diagnosis

• Ankle-brachial Index (ABI)
• Doppler Ultrasound
• Echocardiogram
• Electrocardiogram (ECG)
• Blood Tests
• Others

Treatment

• Medication
• Anti-Platelet Drugs
• Cholesterol Lowering Medications
• Beta Blockers
• Angiotensin-Converting Enzyme (Ace) Inhibitors
• Calcium Channel Blockers
• Others
• Surgery
• Coronary artery bypass surgery
• Fibrinolytic therapy
• Endarterectomy
• Angioplasty
• Others

Route of Administration

• Oral
• Parenteral
• Others

End-Users

• Hospitals
• Specialty Clinics
• Homecare
• Others

Distribution Channel

• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy
• Others

Atherosclerosis Market Regional Analysis/Insights

The atherosclerosis market is analysed and market size insights and trends are provided by country, stages, diagnosis, treatment, route of administration, end-users and distribution channel as referenced above.

The countries covered in the atherosclerosis market report are U.S., Canada and Mexico in North America, Germany, France, U.K., Netherlands, Switzerland, Belgium, Russia, Italy, Spain, Turkey, Rest of Europe in Europe, China, Japan, India, South Korea, Singapore, Malaysia, Australia, Thailand, Indonesia, Philippines, Rest of Asia-Pacific (APAC) in the Asia-Pacific (APAC), Saudi Arabia, U.A.E, South Africa, Egypt, Israel, Rest of Middle East and Africa (MEA) as a part of Middle East and Africa (MEA), Brazil, Argentina and Rest of South America as part of South America

North America dominates the atherosclerosis market because of the rising prevalence of atherosclerosis and technological advancement in the treatment in this region. Additionally, rising healthcare expenditure and presence of major key players will further propel the market's growth rate in this region.

Asia-Pacific are expected to grow during the forecast period of 2022-2029 due to increasing number of geriatric population and surging level of disposable income in this region. Also, development of healthcare infrastructure and rising government initiatives will further propel the market's growth rate in this region.

The country section of the report also provides individual market impacting factors and changes in regulation in the market domestically that impacts the current and future trends of the market. Data points like down-stream and upstream value chain analysis, technical trends and porter's five forces analysis, case studies are some of the pointers used to forecast the market scenario for individual countries. Also, the presence and availability of global brands and their challenges faced due to large or scarce competition from local and domestic brands, impact of domestic tariffs and trade routes are considered while providing forecast analysis of the country data.   

Competitive Landscape and Atherosclerosis Market Share Analysis

The atherosclerosis market competitive landscape provides details by competitor. Details included are company overview, company financials, revenue generated, market potential, investment in research and development, new market initiatives, global presence, production sites and facilities, production capacities, company strengths and weaknesses, product launch, product width and breadth, application dominance. The above data points provided are only related to the companies' focus related to atherosclerosis market.

Some of the major players operating in the atherosclerosis market are:

• F. Hoffmann-La Roche Ltd. (Switzerland)
• Mylan N.V. (U.S.)
• Teva Pharmaceutical Industries Ltd. (Ireland)
• Sanofi (France)
• Pfizer Inc. (U.S.)
• GlaxoSmithKline plc (U.K.)
• Novartis AG (Switzerland)
• Merck & Co., Inc. (U.S.)
• Allergan (Ireland)
• AstraZeneca (U.K.)
• Johnson & Johnson Private Limited (США)
• Hikma Pharmaceuticals PLC (Великобритания)
• Компания Bristol-Myers Squibb (США)
• Bayer AG (Германия)
• Boehringer Ingelheim International GmbH. (Германия)
• Dr. Reddy's Laboratories Ltd. (Индия)
• Gilead Sciences, Inc. (США)
• Amgen Inc. (США)
• Eli Lilly and Company (США)
• AbbVie Inc. (США)
• Люпин (Индия)
• Аллерган (Ирландия)

SKU-53468